Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. notice of proposed affiliate sales under Form 144. The filing lists scheduled restricted stock lapses of 33 shares on 09/17/2025 and 217 shares on 10/17/2025, and a stock option exercise for 1,000 shares on 05/20/2026 described as a broker payment for a cashless exercise. The filing also reports a sale of 1,300 shares by Manuel Hidalgo Medina on 03/06/2026 for $118,997.
Guardant Health director Tariq Musa exercised equity awards and made a small stock sale. On May 15, 2026, 250 restricted stock units converted into common shares, and on May 18, 2026 he sold 116 common shares at $95.96 each, leaving 8,662 shares held directly.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On May 17, 2026, 232 RSUs converted into 232 shares of common stock at a stated price of $0.00 per share, reflecting a vesting event rather than an open-market purchase.
Following the transaction, he held 1,889 shares of common stock directly and 6,033 restricted stock units. The RSU grant, awarded on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health Chief Technology Officer Darya Chudova had 8,705 Restricted Stock Units convert into Common Stock on May 15, 2026. To cover tax obligations, 4,679 shares of Common Stock were retained by Guardant Health, and she now directly holds 74,402 shares.
Guardant Health, Inc. (GH) reported proposed resale transactions under Rule 144 by an affiliate. The filing lists planned restricted-stock-related sales of 80 shares with a 12/15/2025 lapse date and 36 shares with a 02/15/2026 lapse date. The filing also records recent sales by Musa Tariq of 348 shares (03/18/2026) and 116 shares (04/16/2026).
Guardant Health Inc. ownership filing by T. Rowe Price Associates, Inc. reports beneficial ownership of 7,035,771 shares of Common Stock, representing 5.4% of the class as of 03/31/2026. The filing lists sole voting power for 6,842,514 shares and sole dispositive power for 7,035,771 shares. The filing is signed by Ellen York, Vice President, on 05/15/2026.
Guardant Health, Inc. Co-Chief Executive Officer and director AmirAli Talasaz reported an open-market sale of 50,000 shares of Common Stock on May 12, 2026. The shares were sold at a weighted average price of $100.32 per share in multiple trades.
After this transaction, 2,096,504 shares of Guardant Health Common Stock are reported as indirectly owned, held by the Talasaz and Eskandari 2017 Family Trust.
GH filed a Rule 144 notice identifying multiple classes of Common Stock and equity awards subject to sale or disposition. The excerpt lists specific lots, dates and quantities including open market purchases, restricted stock units, stock options and founder shares with entries such as 100,000 founder shares (09/22/2018) and smaller award lots dated between 2020 and 2024.
Guardant Health, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $301.7 million from $203.5 million a year earlier, driven by oncology, biopharma and data, and a sharp increase in screening revenue.
The company posted a net loss of $112.1 million, compared with a $95.2 million loss, with higher sales and marketing and ongoing R&D spending. Cash, cash equivalents and restricted cash totaled $1.10 billion, while convertible senior notes had a net carrying amount of $1.50 billion, leaving Guardant in a stockholders’ deficit of $181.1 million.
Guardant continues to expand its precision oncology and colorectal screening portfolio, including FDA‑approved Shield and Guardant360 tests, while managing significant legal matters. A prior $83.4 million patent verdict against the company remains under challenge, and Guardant has a $287.0 million false‑advertising judgment in its favor in separate litigation.
Guardant Health reported strong first-quarter 2026 growth and raised its full-year 2026 revenue guidance to $1.30–$1.32 billion, implying 32%–34% growth over 2025. Revenue for the quarter rose 48% to $301.7 million, led by oncology revenue of $205.0 million, screening revenue of $41.6 million, and biopharma and data revenue of $53.0 million.
Non-GAAP gross margin improved to 66%, while non-GAAP operating expenses rose to $268.1 million as the company invested in commercial expansion, particularly for its Shield screening business. Guardant remained loss-making, with GAAP net loss of $112.1 million and non-GAAP net loss of $58.7 million, and free cash flow of negative $71.2 million.
The company now expects screening revenue of $186–$198 million in 2026, driven by 230,000–245,000 Shield tests, and continues to target full-year non-GAAP gross margin of 64%–65% and free cash flow burn of $185–$195 million, better than 2025. Cash, cash equivalents, restricted cash and marketable securities totaled about $1.2 billion as of March 31, 2026.